Trial Profile
A Multi-Center, Randomized, Double-Blind, Active-controlled, Parallel-Group, Phase 3, Therapeutic Confirmatory Study to Evaluate the Efficacy and Safety of DWP14012 in Patients With Erosive Gastroesophageal Reflux Disease
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 17 Nov 2020
Price :
$35
*
At a glance
- Drugs Fexuprazan (Primary) ; Esomeprazole
- Indications Erosive oesophagitis; Gastro-oesophageal reflux
- Focus Registrational; Therapeutic Use
- Sponsors Daewoong Pharmaceutical
- 06 Nov 2020 Results presented in the Daewoong Pharmaceutical Media Release.
- 19 May 2020 Primary endpoint has been met. (Cumulative healing rate of erosive esophagitis at 8week by endoscopy)
- 19 May 2020 Results published in Gasteroenterology in conjunction with Digestive Disease Week 2020